Synlogic, Inc. (SYBX)
SYBX Stock Price Chart
Explore Synlogic, Inc. interactive price chart. Choose custom timeframes to analyze SYBX price movements and trends.
SYBX Company Profile
Discover essential business fundamentals and corporate details for Synlogic, Inc. (SYBX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Sept 2015
Employees
1.00
Website
https://www.synlogictx.comCEO
Mary Beth Dooley
Description
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
SYBX Financial Timeline
Browse a chronological timeline of Synlogic, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.11.
Earnings released on 7 Aug 2025
EPS came in at -$0.04 surpassing the estimated -$0.13 by +69.23%.
Earnings released on 6 Mar 2025
EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%.
Earnings released on 12 Nov 2024
EPS came in at -$0.01 surpassing the estimated -$0.18 by +94.44%.
Earnings released on 8 Aug 2024
EPS came in at $0.16 surpassing the estimated -$0.51 by +131.37%.
Earnings released on 14 May 2024
EPS came in at -$2.60 falling short of the estimated -$0.80 by -225.00%, while revenue for the quarter reached $8.00K .
Earnings released on 19 Mar 2024
EPS came in at -$1.71 falling short of the estimated -$1.11 by -54.05%, while revenue for the quarter reached $2.77M , beating expectations by +1.30%.
Earnings released on 9 Nov 2023
EPS came in at -$2.57 falling short of the estimated -$2.55 by -0.78%, while revenue for the quarter reached $393.00K , missing expectations by -84.88%.
Stock split effective on 28 Sept 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Aug 2023
EPS came in at -$3.15 surpassing the estimated -$3.90 by +19.23%, while revenue for the quarter reached $35.00K , missing expectations by -73.08%.
Earnings released on 11 May 2023
EPS came in at -$3.45 surpassing the estimated -$3.75 by +8.00%, while revenue for the quarter reached $174.00K , beating expectations by +24.29%.
Earnings released on 29 Mar 2023
EPS came in at -$3.60 surpassing the estimated -$3.90 by +7.69%, while revenue for the quarter reached $106.00K , missing expectations by -51.82%.
Earnings released on 10 Nov 2022
EPS came in at -$3.75 falling short of the estimated -$3.45 by -8.70%, while revenue for the quarter reached $678.00K , beating expectations by +674.86%.
Earnings released on 11 Aug 2022
EPS came in at -$3.30 surpassing the estimated -$3.45 by +4.35%, while revenue for the quarter reached $152.00K , beating expectations by +1.33%.
Earnings released on 12 May 2022
EPS came in at -$3.30 surpassing the estimated -$3.45 by +4.35%, while revenue for the quarter reached $244.00K , beating expectations by +52.50%.
Earnings released on 17 Mar 2022
EPS came in at -$3.15 surpassing the estimated -$4.05 by +22.22%, while revenue for the quarter reached $592.00K , beating expectations by +228.89%.
Earnings released on 10 Nov 2021
EPS came in at -$4.35 matching the estimated -$4.35, while revenue for the quarter reached $916.00K , meeting expectations.
Earnings released on 12 Aug 2021
EPS came in at -$4.20 surpassing the estimated -$4.35 by +3.45%, while revenue for the quarter reached $246.00K , beating expectations by +720.00%.
Earnings released on 13 May 2021
EPS came in at -$5.40 surpassing the estimated -$5.85 by +7.69%.
Earnings released on 25 Mar 2021
EPS came in at -$5.85 surpassing the estimated -$6.00 by +2.50%, while revenue for the quarter reached $0.00 .
Earnings released on 5 Nov 2020
EPS came in at -$5.40 surpassing the estimated -$7.05 by +23.40%.
SYBX Stock Performance
Access detailed SYBX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.